Abstract
Studies investigating neurobiological bases of negative symptoms of schizophrenia failed to provide consistent findings, possibly due to the heterogeneity of this psychopathological construct. We tried to review the findings published to date investigating neurobiological abnormalities after reducing the heterogeneity of the negative symptoms construct. The literature in electronic databases as well as citations and major articles are reviewed with respect to the phenomenology, pathology, genetics and neurobiology of schizophrenia. We searched PubMed with the keywords “negative symptoms,” “deficit schizophrenia,” “persistent negative symptoms,” “neurotransmissions,” “neuroimaging” and “genetic.” Additional articles were identified by manually checking the reference lists of the relevant publications. Publications in English were considered, and unpublished studies, conference abstracts and poster presentations were not included. Structural and functional imaging studies addressed the issue of neurobiological background of negative symptoms from several perspectives (considering them as a unitary construct, focusing on primary and/or persistent negative symptoms and, more recently, clustering them into factors), but produced discrepant findings. The examined studies provided evidence suggesting that even primary and persistent negative symptoms include different psychopathological constructs, probably reflecting the dysfunction of different neurobiological substrates. Furthermore, they suggest that complex alterations in multiple neurotransmitter systems and genetic variants might influence the expression of negative symptoms in schizophrenia. On the whole, the reviewed findings, representing the distillation of a large body of disparate data, suggest that further deconstruction of negative symptomatology into more elementary components is needed to gain insight into underlying neurobiological mechanisms.
Similar content being viewed by others
References
Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32(2):214–219
Carpenter WT Jr, Heinrichs DW, Wagman AM (1988) Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 145(5):578–583
Galderisi S, Maj M, Mucci A, Cassano GB, Invernizzi G, Rossi A, Vita A, Dell’Osso L, Daneluzzo E, Pini S (2002) Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry 159(6):983–990
Kirkpatrick B, Galderisi S (2008) Deficit schizophrenia: an update. World Psychiatry Off J World Psychiatr Assoc 7(3):143–147
Galderisi S, Maj M (2009) Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur Psychiatry Journal Assoc Eur Psychiatr 24(8):493–500
Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW (2007) Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull 33(5):1201–1212
Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr (1998) Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155(6):751–760
Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr (2001) A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 58(2):165–171
Galderisi S, Bucci P, Mucci A, Kirkpatrick B, Pini S, Rossi A, Vita A, Maj M (2013) Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res 147(1):157–162
Kirkpatrick B, Fischer B (2006) Subdomains within the negative symptoms of schizophrenia: commentary. Schizophr Bull 32(2):246–249
Blanchard JJ, Cohen AS (2006) The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 32(2):238–245
Buchanan RW (2007) Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 33(4):1013–1022
O’Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC (2000) Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 12(1):4–15
Bodnar M, Malla A, Joober R, Lepage M (2008) Cognitive markers of short-term clinical outcome in first-episode psychosis. Br J Psychiatry 193(4):297–304
Hovington CL, Bodnar M, Joober R, Malla AK, Lepage M (2012) Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry 12:224
Galderisi S, Mucci A, Bitter I, Libiger J, Bucci P, Fleischhacker WW, Kahn RS, Eufest Study G (2013) Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol 23(3):196–204
Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR (2011) The brief negative symptom scale: psychometric properties. Schizophr Bull 37(2):300–305
Strauss GP, Hong LE, Gold JM, Buchanan RW, McMahon RP, Keller WR, Fischer BA, Catalano LT, Culbreth AJ, Carpenter WT, Kirkpatrick B (2012) Factor structure of the Brief Negative Symptom Scale. Schizophr Res 142(1–3):96–98
Kimhy D, Yale S, Goetz RR, McFarr LM, Malaspina D (2006) The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull 32(2):274–278
Nakaya M, Ohmori K (2008) A two-factor structure for the Schedule for the Deficit Syndrome in schizophrenia. Psychiatry Res 158(2):256–259
Messinger JW, Tremeau F, Antonius D, Mendelsohn E, Prudent V, Stanford AD, Malaspina D (2011) Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research. Clin Psychol Rev 31(1):161–168
Strauss GP, Horan WP, Kirkpatrick B, Fischer BA, Keller WR, Miski P, Buchanan RW, Green MF, Carpenter WT Jr (2013) Deconstructing negative symptoms of schizophrenia: avolition–apathy and diminished expression clusters predict clinical presentation and functional outcome. Psychiatry Res 47(6):783–790
Kemali D, Maj M, Galderisi S, Salvati A, Starace F, Valente A, Pirozzi R (1987) Clinical, biological, and neuropsychological features associated with lateral ventricular enlargement in DSM-III schizophrenic disorder. Psychiatry Res 21(2):137–149
Andreasen NC, Swayze VW, Flaum M, Yates WR, Arndt S, McChesney C (1990) Ventricular enlargement in schizophrenia evaluated with computed tomographic scanning. Effects of gender, age, and stage of illness. Arch Gen Psychiatry 47(11):1008–1015
Johnstone EC, Bruton CJ, Crow TJ, Frith CD, Owens DG (1994) Clinical correlates of postmortem brain changes in schizophrenia: decreased brain weight and length correlate with indices of early impairment. J Neurol Neurosurg Psychiatry 57(4):474–479
Saijo T, Abe T, Someya Y, Sassa T, Sudo Y, Suhara T, Shuno T, Asai K, Okubo Y (2001) Ten year progressive ventricular enlargement in schizophrenia: an MRI morphometrical study. Psychiatry Clin Neurosci 55(1):41–47
Keilp JG, Sweeney JA, Jacobsen P, Solomon C, St Louis L, Deck M, Frances A, Mann JJ (1988) Cognitive impairment in schizophrenia: specific relations to ventricular size and negative symptomatology. Biol Psychiatry 24(1):47–55
Pfefferbaum A, Zipursky RB, Lim KO, Zatz LM, Stahl SM, Jernigan TL (1988) Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. Arch Gen Psychiatry 45(7):633–640
Bishop RJ, Golden CJ, MacInnes WD, Chu CC, Ruedrich SL, Wilson J (1983) The BPRS in assessing symptom correlates of cerebral ventricular enlargement in acute and chronic schizophrenia. Psychiatry Res 9(3):225–231
Luchins DJ, Lewine RR, Meltzer HY (1984) Lateral ventricular size, psychopathology, and medication response in the psychoses. Biol Psychiatry 19(1):29–44
Andreasen NC (1989) Neural mechanisms of negative symptoms. Br J Psychiatry 7:93–98
Berman KF, Illowsky BP, Weinberger DR (1988) Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. IV. Further evidence for regional and behavioral specificity. Arch Gen Psychiatry 45(7):616–622
Weinberger DR, Berman KF (1988) Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr Bull 14(2):157–168
Goff DC, Evins AE (1998) Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv Rev Psychiatry 6(2):59–77
Kirkpatrick B, Buchanan RW (1990) The neural basis of the deficit syndrome of schizophrenia. J Nerv Ment Dis 178(9):545–555
Goghari VM, Sponheim SR, MacDonald AW 3rd (2010) The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question. Neurosci Biobehav Rev 34(3):468–486
Andreasen N, Nasrallah HA, Dunn V, Olson SC, Grove WM, Ehrhardt JC, Coffman JA, Crossett JH (1986) Structural abnormalities in the frontal system in schizophrenia. A magnetic resonance imaging study. Arch Gen Psychiatry 43(2):136–144
DeMyer MK, Gilmor RL, Hendrie HC, DeMyer WE, Augustyn GT, Jackson RK (1988) Magnetic resonance brain images in schizophrenic and normal subjects: influence of diagnosis and education. Schizophr Bull 14(1):21–37
Raine A, Lencz T, Reynolds GP, Harrison G, Sheard C, Medley I, Reynolds LM, Cooper JE (1992) An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Res 45(2):123–137
Turetsky B, Cowell PE, Gur RC, Grossman RI, Shtasel DL, Gur RE (1995) Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch Gen Psychiatry 52(12):1061–1070
Baare WF, Hulshoff Pol HE, Hijman R, Mali WP, Viergever MA, Kahn RS (1999) Volumetric analysis of frontal lobe regions in schizophrenia: relation to cognitive function and symptomatology. Biol Psychiatry 45(12):1597–1605
Wible CG, Anderson J, Shenton ME, Kricun A, Hirayasu Y, Tanaka S, Levitt JJ, O’Donnell BF, Kikinis R, Jolesz FA, McCarley RW (2001) Prefrontal cortex, negative symptoms, and schizophrenia: an MRI study. Psychiatry Res 108(2):65–78
Hazlett EA, Buchsbaum MS, Haznedar MM, Newmark R, Goldstein KE, Zelmanova Y, Glanton CF, Torosjan Y, New AS, Lo JN, Mitropoulou V, Siever LJ (2008) Cortical gray and white matter volume in unmedicated schizotypal and schizophrenia patients. Schizophr Res 101(1–3):111–123
Koutsouleris N, Gaser C, Jager M, Bottlender R, Frodl T, Holzinger S, Schmitt GJ, Zetzsche T, Burgermeister B, Scheuerecker J, Born C, Reiser M, Moller HJ, Meisenzahl EM (2008) Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. NeuroImage 39(4):1600–1612
Nesvag R, Saetre P, Lawyer G, Jonsson EG, Agartz I (2009) The relationship between symptom severity and regional cortical and grey matter volumes in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33(3):482–490
Lacerda AL, Hardan AY, Yorbik O, Vemulapalli M, Prasad KM, Keshavan MS (2007) Morphology of the orbitofrontal cortex in first-episode schizophrenia: relationship with negative symptomatology. Prog Neuropsychopharmacol Biol Psychiatry 31(2):510–516
Young AH, Blackwood DH, Roxborough H, McQueen JK, Martin MJ, Kean D (1991) A magnetic resonance imaging study of schizophrenia: brain structure and clinical symptoms. Br J Psychiatry 158:158–164
Zetzsche T, Preuss UW, Frodl T, Leinsinger G, Born C, Reiser M, Hegerl U, Moller HJ, Meisenzahl EM (2008) White matter alterations in schizophrenic patients with pronounced negative symptomatology and with positive family history for schizophrenia. Eur Arch Psychiatry Clin Neurosci 258(5):278–284
Nestor PG, Onitsuka T, Gurrera RJ, Niznikiewicz M, Frumin M, Shenton ME, McCarley RW (2007) Dissociable contributions of MRI volume reductions of superior temporal and fusiform gyri to symptoms and neuropsychology in schizophrenia. Schizophr Res 91(1–3):103–106
Tibbo P, Nopoulos P, Arndt S, Andreasen NC (1998) Corpus callosum shape and size in male patients with schizophrenia. Biol Psychiatry 44(6):405–412
Kim JJ, Crespo-Facorro B, Andreasen NC, O’Leary DS, Magnotta V, Nopoulos P (2003) Morphology of the lateral superior temporal gyrus in neuroleptic naive patients with schizophrenia: relationship to symptoms. Schizophr Res 60(2–3):173–181
Szendi I, Kiss M, Racsmany M, Boda K, Cimmer C, Voros E, Kovacs ZA, Szekeres G, Galsi G, Pleh C, Csernay L, Janka Z (2006) Correlations between clinical symptoms, working memory functions and structural brain abnormalities in men with schizophrenia. Psychiatry Res 147(1):47–55
Pakkenberg B (1987) Post-mortem study of chronic schizophrenic brains. Br J Psychiatry 151:744–752
Powchik P, Davidson M, Haroutunian V, Gabriel SM, Purohit DP, Perl DP, Harvey PD, Davis KL (1998) Postmortem studies in schizophrenia. Schizophr Bull 24(3):325–341
Kawasaki Y, Maeda Y, Suzuki M, Urata K, Higashima M, Kiba K, Yamaguchi N, Matsuda H, Hisada K (1993) SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test. Schizophr Res 10(2):109–116
Ebmeier KP, Blackwood DH, Murray C, Souza V, Walker M, Dougall N, Moffoot AP, O’Carroll RE, Goodwin GM (1993) Single-photon emission computed tomography with 99 mTc-exametazime in unmedicated schizophrenic patients. Biol Psychiatry 33(7):487–495
Klemm E, Danos P, Grunwald F, Kasper S, Moller HJ, Biersack HJ (1996) Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression–a study with single photon emission computed tomography. Psychiatry Res 68(1):1–10
Schroder J, Buchsbaum MS, Siegel BV, Geider FJ, Lohr J, Tang C, Wu J, Potkin SG (1996) Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schizophr Res 19(1):41–53
Sabri O, Erkwoh R, Schreckenberger M, Cremerius U, Schulz G, Dickmann C, Kaiser HJ, Steinmeyer EM, Sass H, Buell U (1997) Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. J Nucl Med 38(2):181–188
Erkwoh R, Sabri O, Steinmeyer EM, Bull U, Sass H (1997) Psychopathological and SPECT findings in never-treated schizophrenia. Acta Psychiatr Scand 96(1):51–57
Heckers S, Goff D, Schacter DL, Savage CR, Fischman AJ, Alpert NM, Rauch SL (1999) Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Arch Gen Psychiatry 56(12):1117–1123
Andreasen NC, Rezai K, Alliger R, Swayze VW 2nd, Flaum M, Kirchner P, Cohen G, O’Leary DS (1992) Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 49(12):943–958
Siegel BV Jr, Buchsbaum MS, Bunney WE Jr, Gottschalk LA, Haier RJ, Lohr JB, Lottenberg S, Najafi A, Nuechterlein KH, Potkin SG et al (1993) Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry 150(9):1325–1336
Erkwoh R, Sabri O, Willmes K, Steinmeyer EM, Bull U, Sass H (1999) Active and remitted schizophrenia: psychopathological and regional cerebral blood flow findings. Psychiatry Res 90(1):17–30
Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J (1992) Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 49(12):959–965
Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT (1992) Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49(7):522–530
Potkin SG, Alva G, Fleming K, Anand R, Keator D, Carreon D, Doo M, Jin Y, Wu JC, Fallon JH (2002) A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am J Psychiatry 159(2):227–237
Vita A, Bressi S, Perani D, Invernizzi G, Giobbio GM, Dieci M, Garbarini M, Del Sole A, Fazio F (1995) High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. Am J Psychiatry 152(6):876–882
Min SK, An SK, Jon DI, Lee JD (1999) Positive and negative symptoms and regional cerebral perfusion in antipsychotic-naive schizophrenic patients: a high-resolution SPECT study. Psychiatry Res 90(3):159–168
Yuasa S, Kurachi M, Suzuki M, Kadono Y, Matsui M, Saitoh O, Seto H (1995) Clinical symptoms and regional cerebral blood flow in schizophrenia. Eur Arch Psychiatry Clin Neurosci 246(1):7–12
Gur RE, Mozley PD, Resnick SM, Mozley LH, Shtasel DL, Gallacher F, Arnold SE, Karp JS, Alavi A, Reivich M et al (1995) Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features. Arch Gen Psychiatry 52(8):657–667
Nielsen MO, Rostrup E, Wulff S, Bak N, Broberg BV, Lublin H, Kapur S, Glenthoj B (2012) Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry 69(12):1195–1204
Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A, Knutson B, Kienast T, Gallinat J, Wrase J, Heinz A (2006) Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology 187(2):222–228
Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, Wrase J, Heinz A (2006) Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 29(2):409–416
Schlagenhauf F, Sterzer P, Schmack K, Ballmaier M, Rapp M, Wrase J, Juckel G, Gallinat J, Heinz A (2009) Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biol Psychiatry 65(12):1032–1039
Nielsen MO, Rostrup E, Wulff S, Bak N, Lublin H, Kapur S, Glenthoj B (2012) Alterations of the brain reward system in antipsychotic naive schizophrenia patients. Biol Psychiatry 71(10):898–905
Waltz JA, Schweitzer JB, Ross TJ, Kurup PK, Salmeron BJ, Rose EJ, Gold JM, Stein EA (2010) Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology 35(12):2427–2439
Walter H, Kammerer H, Frasch K, Spitzer M, Abler B (2009) Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology 206(1):121–132
Schlagenhauf F, Juckel G, Koslowski M, Kahnt T, Knutson B, Dembler T, Kienast T, Gallinat J, Wrase J, Heinz A (2008) Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology 196(4):673–684
Simon JJ, Biller A, Walther S, Roesch-Ely D, Stippich C, Weisbrod M, Kaiser S (2010) Neural correlates of reward processing in schizophrenia relationship to apathy and depression. Schizophr Res 118(1–3):154–161
Esslinger C, Englisch S, Inta D, Rausch F, Schirmbeck F, Mier D, Kirsch P, Meyer-Lindenberg A, Zink M (2012) Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients. Schizophr Res 140(1–3):114–121
Grover S, Kulhara P (2008) Deficit schizophrenia: Concept and validity. Indian J Psychiatry 50(1):61–66
Kring AM, Elis O (2013) Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol 9:409–433
Gur RE, Mozley PD, Shtasel DL, Cannon TD, Gallacher F, Turetsky B, Grossman R, Gur RC (1994) Clinical subtypes of schizophrenia: differences in brain and CSF volume. Am J Psychiatry 151(3):343–350
Quarantelli M, Larobina M, Volpe U, Amati G, Tedeschi E, Ciarmiello A, Brunetti A, Galderisi S, Alfano B (2002) Stereotaxy-based regional brain volumetry applied to segmented MRI: validation and results in deficit and nondeficit schizophrenia. NeuroImage 17(1):373–384
Galderisi S, Quarantelli M, Volpe U, Mucci A, Cassano GB, Invernizzi G, Rossi A, Vita A, Pini S, Cassano P, Daneluzzo E, De Peri L, Stratta P, Brunetti A, Maj M (2008) Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr Bull 34(2):393–401
Sigmundsson T, Suckling J, Maier M, Williams S, Bullmore E, Greenwood K, Fukuda R, Ron M, Toone B (2001) Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. Am J Psychiatry 158(2):234–243
Arango C, McMahon RP, Lefkowitz DM, Pearlson G, Kirkpatrick B, Buchanan RW (2008) Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res 162(2):91–100
Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, Carpenter WT Jr (1993) Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry 150(1):59–65
Volpe U, Mucci A, Quarantelli M, Galderisi S, Maj M (2012) Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 37(2):264–269
Fisher DJ, Labelle A, Knott VJ (2012) Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness. Schizophr Res 139(1–3):237–245
Gur RE, Jaggi JL, Shtasel DL, Ragland JD, Gur RC (1994) Cerebral blood flow in schizophrenia: effects of memory processing on regional activation. Biol Psychiatry 35(1):3–15
Mozley PD, Gur RE, Resnick SM, Shtasel DL, Richards J, Kohn M, Grossman R, Herman G, Gur RC (1994) Magnetic resonance imaging in schizophrenia: relationship with clinical measures. Schizophr Res 12(3):195–203
Cascella NG, Fieldstone SC, Rao VA, Pearlson GD, Sawa A, Schretlen DJ (2010) Gray-matter abnormalities in deficit schizophrenia. Schizophr Res 120(1–3):63–70
Takayanagi M, Wentz J, Takayanagi Y, Schretlen DJ, Ceyhan E, Wang L, Suzuki M, Sawa A, Barta PE, Ratnanather JT, Cascella NG (2013) Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia. Schizophr Res 150(2–3):484–490
Ozdemir HI, Eker MC, Zengin B, Yilmaz DA, Isman Haznedaroglu D, Cinar C, Kitis O, Akay A, Gonul AS (2012) Gray matter changes in patients with deficit schizophrenia and non-deficit schizophrenia. Turk Psikiyatri Derg 23(4):237–246
Rowland LM, Spieker EA, Francis A, Barker PB, Carpenter WT, Buchanan RW (2009) White matter alterations in deficit schizophrenia. Neuropsychopharmacology 34(6):1514–1522
Kitis O, Ozalay O, Zengin EB, Haznedaroglu D, Eker MC, Yalvac D, Oguz K, Coburn K, Gonul AS (2012) Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia. Psychiatry Clin Neurosci 66(1):34–43
Voineskos AN, Foussias G, Lerch J, Felsky D, Remington G, Rajji TK, Lobaugh N, Pollock BG, Mulsant BH (2013) Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA psychiatry 70(5):472–480
Lahti AC, Holcomb HH, Medoff DR, Weiler MA, Tamminga CA, Carpenter WT Jr (2001) Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry 158(11):1797–1808
Vaiva G, Cottencin O, Llorca PM, Devos P, Dupont S, Mazas O, Rascle C, Thomas P, Steinling M, Goudemand M (2002) Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Prog Neuropsychopharmacol Biol Psychiatry 26(3):481–485
Gonul AS, Kula M, Esel E, Tutus A, Sofuoglu S (2003) A Tc-99 m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Res 123(3):199–205
Kanahara N, Sekine Y, Haraguchi T, Uchida Y, Hashimoto K, Shimizu E, Iyo M (2013) Orbitofrontal cortex abnormality and deficit schizophrenia. Schizophr Res 143(2–3):246–252
Mucci A, Dima D, Soricelli A, Volpe U, Bucci P, Frangou S, Prinster A, Salvatore M, Galderisi S, Maj M (2015) Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. Psychol Med 12:1–14
Castellon SA, Asarnow RF, Goldstein MJ, Marder SR (1994) Persisting negative symptoms and information-processing deficits in schizophrenia: implications for subtyping. Psychiatry Res 54(1):59–69
Tandon R, DeQuardo JR, Taylor SF, McGrath M, Jibson M, Eiser A, Goldman M (2000) Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome. Schizophr Res 45(3):191–201
Mancevski B, Keilp J, Kurzon M, Berman RM, Ortakov V, Harkavy-Friedman J, Rosoklija G, Dwork AJ (2007) Lifelong course of positive and negative symptoms in chronically institutionalized patients with schizophrenia. Psychopathology 40(2):83–92
Hovington CL, Lepage M (2012) Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Rev Neurother 12(1):53–69
Benoit A, Bodnar M, Malla AK, Joober R, Lepage M (2012) The structural neural substrates of persistent negative symptoms in first-episode of non-affective psychosis: a voxel-based morphometry study. Front Psychiatry 3:42
Fahim C, Stip E, Mancini-Marie A, Mensour B, Boulay LJ, Leroux JM, Beaudoin G, Bourgouin P, Beauregard M (2005) Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: an fMRI study. Psychiatry Res 140(1):1–15
Gur RE, Loughead J, Kohler CG, Elliott MA, Lesko K, Ruparel K, Wolf DH, Bilker WB, Gur RC (2007) Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch Gen Psychiatry 64(12):1356–1366
Lepage M, Sergerie K, Benoit A, Czechowska Y, Dickie E, Armony JL (2011) Emotional face processing and flat affect in schizophrenia: functional and structural neural correlates. Psychol Med 41(9):1833–1844
Horan WP, Kring AM, Blanchard JJ (2006) Anhedonia in schizophrenia: a review of assessment strategies. Schizophr Bull 32(2):259–273
Burbridge JA, Barch DM (2007) Anhedonia and the experience of emotion in individuals with schizophrenia. J Abnorm Psychol 116(1):30–42
Gard DE, Kring AM, Gard MG, Horan WP, Green MF (2007) Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res 93(1–3):253–260
Herbener ES, Song W, Khine TT, Sweeney JA (2008) What aspects of emotional functioning are impaired in schizophrenia? Schizophr Res 98(1–3):239–246
Barch DM, Dowd EC (2010) Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull 36(5):919–934
Pizzagalli DA (2010) The “anhedonia paradox” in schizophrenia: insights from affective neuroscience. Biol Psychiatry 67(10):899–901
Simpson EH, Waltz JA, Kellendonk C, Balsam PD (2012) Schizophrenia in translation: dissecting motivation in schizophrenia and rodents. Schizophr Bull 38(6):1111–1117
Castner SA, Goldman-Rakic PS (1999) Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 1:10–28
Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97(14):8104–8109
Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148(11):1474–1486
Seeman P, Van Tol HH (1994) Dopamine receptor pharmacology. Trends Pharmacol Sci 15(7):264–270
Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T (1999) Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 96(23):13432–13437
Heinz A (2000) The dopamine hypothesis of schizophrenia. New findings for an old theory. Nervenarzt 71(1):54–57
Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M (2004) Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 161(10):1798–1805
Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385(6617):634–636
Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22(9):3708–3719
Karlsson P, Farde L, Halldin C, Sedvall G (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159(5):761–767
Nolte S, Wong D, Lachford G (2004) Amphetamines for schizophrenia. Cochrane Database Syst Rev 18(4):CD004964
Dolan RJ, Fletcher P, Frith CD, Friston KJ, Frackowiak RS, Grasby PM (1995) Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378(6553):180–182
Pogarell O, Koch W, Karch S, Dehning S, Muller N, Tatsch K, Poepperl G, Moller HJ (2012) Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry 45(Suppl 1):S36–S41
Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, Awad AG (2001) Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 25(5):642–650
Voruganti LN, Awad AG (2006) Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia–findings from an in vivo SPECT study. Schizophr Res 88(1–3):179–186
Heinz A (2002) Dopaminergic dysfunction in alcoholism and schizophrenia–psychopathological and behavioral correlates. Eur Psychiatry 17(1):9–16
Kapur S (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160(1):13–23
Menon M, Mizrahi R, Kapur S (2008) ‘Jumping to conclusions’ and delusions in psychosis: relationship and response to treatment. Schizophr Res ch 98(1–3):225–231
Seamans JK, Yang CR (2004) The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74(1):1–58
Roiser JP, Stephan KE, den Ouden HE, Barnes TR, Friston KJ, Joyce EM (2009) Do patients with schizophrenia exhibit aberrant salience? Psychol Med 39(2):199–209
Strauss GP, Waltz JA, Gold JM (2014) A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull 40(Suppl 2):S107–S116
Ribeyre JM, Lesieur P, Varoquaux O, Dollfus S, Pays M, Petit M (1994) A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 36(4):230–236
Thibaut F, Ribeyre JM, Dourmap N, Menard JF, Dollfus S, Petit M (1998) Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. Biol Psychiatry 43(1):24–30
Nibuya M, Kanba S, Sekiya U, Suzuki E, Matsuo Y, Kinoshita N, Shintani F, Yagi G, Asai M (1995) Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biol Psychiatry 38(1):50–56
Carpenter WT Jr, Breier A, Buchanan RW, Kirkpatrick B, Shepard P, Weiner E (2000) Mazindol treatment of negative symptoms. Neuropsychopharmacology 23(4):365–374
Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO (2005) Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia. Am J Psychiatry 162(2):388–390
Pickar D, Breier A, Hsiao JK, Doran AR, Wolkowitz OM, Pato CN, Konicki PE, William Z, Potter WZ (1990) Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry 47(7):641–648
Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, Wilson AA, Houle S, Kasper S, Zipursky RB (2002) Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 59(6):514–520
Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, Okubo Y (2004) Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 55(5):439–444
Frankle WG, Lombardo I, Kegeles LS, Slifstein M, Martin JH, Huang Y, Hwang DR, Reich E, Cangiano C, Gil R, Laruelle M, Abi-Dargham A (2006) Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. Psychopharmacology 189(2):155–164
Severance EG, Yolken RH (2008) Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. Genes Brain Behav 7(1):37–45
Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165(8):1033–1039
Scarr E, Cowie TF, Kanellakis S, Sundram S, Pantelis C, Dean B (2009) Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 14(11):1017–1023
Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393(1–3):295–314
Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR (2004) Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology 29(2):259–268
Ziedonis DM, Kosten TR, Glazer WM, Frances RJ (1994) Nicotine dependence and schizophrenia. Hosp Community Psychiatry 45(3):204–206
D’Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M (2012) Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia. Biol Psychiatry 72(9):785–794
Luckhaus C, Henning U, Ferrea S, Musso F, Mobascher A, Winterer G (2012) Nicotinic acetylcholine receptor expression on B-lymphoblasts of healthy versus schizophrenic subjects stratified for smoking: [3H]-nicotine binding is decreased in schizophrenia and correlates with negative symptoms. J Neural Transm 119(5):587–595
Rabin RA, Sacco KA, George TP (2009) Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking status. Schizophr Res 114(1–3):91–97
Woznica AA, Sacco KA, George TP (2009) Prepulse inhibition deficits in schizophrenia are modified by smoking status. Schizophr Res 112(1–3):86–90
Winterer G (2010) Why do patients with schizophrenia smoke? Curr Opin Psychiatry 23(2):112–119
Mexal S, Berger R, Logel J, Ross RG, Freedman R, Leonard S (2010) Differential regulation of alpha7 nicotinic receptor gene (CHRNA7) expression in schizophrenic smokers. J Mol Neurosci 40(1–2):185–195
Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63(6):630–638
Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR (2008) Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165(8):1040–1047
Lieberman JA, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA (2013) A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38(6):968–975
Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9(11):984–997, 979
Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69–108
Akbarian S, Huang HS (2006) Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 52(2):293–304
Eyles DW, McGrath JJ, Reynolds GP (2002) Neuronal calcium-binding proteins and schizophrenia. Schizophr Res 57(1):27–34
Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10):1301–1308
Sawa A, Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. Science 296(5568):692–695
Krystal JH, Abi-Saab W, Perry E, D’Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A (2005) Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179(1):303–309
Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27(43):11496–11500
Moghaddam B, Krystal JH (2012) Capturing the angel in “angel dust”: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull 38(5):942–949
Snyder MA, Gao WJ (2013) NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia. Front Cell Neurosci 7:31
Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921–2927
Moghaddam B, Javitt D (2012) From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 37(1):4–15
Stahl SM (2007) Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr 12(4):265–268
Belforte JE, Zsiros V, Sklar ER, Jiang Z, Yu G, Li Y, Quinlan EM, Nakazawa K (2010) Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 13(1):76–83
Schwartz TL, Sachdeva S, Stahl SM (2012) Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol 3:195
Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, Stone JM (2012) Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 37(11):2515–2521
Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS, Knowlton RC, den Hollander JA, Lahti AC (2010) Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry 68(7):625–633
Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, Apfeldorf W, Lauriello J, Posse S (2011) Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry 69(1):19–27
Rowland LM, Kontson K, West J, Edden RA, Zhu H, Wijtenburg SA, Holcomb HH, Barker PB (2013) In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull 39(5):1096–1104
Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, Gil R, Slifstein M, Abi-Dargham A, Lisanby SH, Shungu DC (2012) Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 69(5):449–459
Reid MA, Kraguljac NV, Avsar KB, White DM, den Hollander JA, Lahti AC (2013) Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. Schizophr Res 147(2–3):348–354
Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY (2004) Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms. Int J Neuropsychopharmacol 7(1):1–8
Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U (2005) Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 162(9):1738–1740
Tuominen HJ, Tiihonen J, Wahlbeck K (2005) Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72(2–3):225–234
Diaz P, Bhaskara S, Dursun SM, Deakin B (2005) Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results. J Clin Psychopharmacol 25(3):277–278
Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA (2013) Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. Curr Top Med Chem 13(1):26–54
Profaci CP, Krolikowski KA, Olszewski RT, Neale JH (2011) Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia. Psychopharmacology 216(2):235–243
Wischhof L, Aho HE, Koch M (2012) DOI-induced deficits in prepulse inhibition in Wistar rats are reversed by mGlu2/3 receptor stimulation. Pharmacol Biochem Behav 102(1):6–12
Inta D, Vogt MA, Perreau-Lenz S, Schneider M, Pfeiffer N, Wojcik SM, Spanagel R, Gass P (2012) Sensorimotor gating, working and social memory deficits in mice with reduced expression of the vesicular glutamate transporter VGLUT1. Behav Brain Res 228(2):328–332
Wang ZR, Tan YL, Yang FD, Zhang WF, Zou YZ, Tan SP, Song CS, Li YL, Zhang WH, Zhou DF (2013) Impaired prepulse inhibition of acoustic startle in Chinese patients with first-episode, medication-naive schizophrenia. Chin Med J (Engl) 126(3):526–531
Swerdlow NR, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL (2014) Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res 152(2–3):503–512
Ludewig K, Vollenweider FX (2002) Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. Swiss Med Wkly 132(13–14):159–165
Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA (2008) Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31(5):234–242
Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H (2010) Glutamatergic (N-methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol 77(3):317–326
Minoretti P, Politi P, Coen E, Di Vito C, Bertona M, Bianchi M, Emanuele E (2006) The T393C polymorphism of the GNAS1 gene is associated with deficit schizophrenia in an Italian population sample. Neurosci Lett 397(1–2):159–163
Wonodi I, Mitchell BD, Stine OC, Hong LE, Elliott A, Kirkpatrick B, Carpenter WT Jr, Thaker GK, Buchanan RW (2006) Lack of association between COMT gene and deficit/nondeficit schizophrenia. Behav Brain Funct 2:42
Bakker SC, Hoogendoorn ML, Hendriks J, Verzijlbergen K, Caron S, Verduijn W, Selten JP, Pearson PL, Kahn RS, Sinke RJ (2007) The PIP5K2A and RGS4 genes are differentially associated with deficit and non-deficit schizophrenia. Genes Brain Behav 6(2):113–119
Wessman J, Paunio T, Tuulio-Henriksson A, Koivisto M, Partonen T, Suvisaari J, Turunen JA, Wedenoja J, Hennah W, Pietilainen OP, Lonnqvist J, Mannila H, Peltonen L (2009) Mixture model clustering of phenotype features reveals evidence for association of DTNBP1 to a specific subtype of schizophrenia. Biol Psychiatry 66(11):990–996
Pelka-Wysiecka J, Wronski M, Jasiewicz A, Grzywacz A, Tybura P, Kucharska-Mazur J, Bienkowski P, Samochowiec J (2013) BDNF rs 6265 polymorphism and COMT rs 4680 polymorphism in deficit schizophrenia in Polish sample. Pharmacol Rep 65(5):1185–1193
Fanous AH, van den Oord EJ, Riley BP, Aggen SH, Neale MC, O’Neill FA, Walsh D, Kendler KS (2005) Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 162(10):1824–1832
DeRosse P, Funke B, Burdick KE, Lencz T, Ekholm JM, Kane JM, Kucherlapati R, Malhotra AK (2006) Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry 163(3):532–534
Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mossner R, Collier DA, Kuhn KU, Maier W, Wagner M, Kumari V (2010) Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology 35(7):1429–1439
Zahari Z, Teh LK, Ismail R, Razali SM (2011) Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia. Psychiatr Genet 21(4):183–189
Itokawa M, Arinami T, Toru M (2010) Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia. J Pharmacol Sci 114(1):1–5
Park HJ, Kim JW, Lee SK, Kim SK, Park JK, Cho AR, Chung JH, Song JY (2011) Association between the SLC6A12 gene and negative symptoms of schizophrenia in a Korean population. Psychiatry Res 189(3):478–479
Pelayo-Teran JM, Crespo-Facorro B, Carrasco-Marin E, Perez-Iglesias R, Mata I, Arranz MJ, Leyva-Cobian F, Vazquez-Barquero JL (2008) Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. Am J Med Genet B Neuropsychiatr Genet 147B(5):550–556
Pelayo-Teran JM, Perez-Iglesias R, Vazquez-Bourgon J, Mata I, Carrasco-Marin E, Vazquez-Barquero JL, Crespo-Facorro B (2011) Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Res 185(1–2):286–289
Wang Y, Fang Y, Shen Y, Xu Q (2010) Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Res 179(2):147–150
McClay JL, Fanous A, van den Oord EJ, Webb BT, Walsh D, O’Neill FA, Kendler KS, Chen X (2006) Catechol-O-methyltransferase and the clinical features of psychosis. Am J Med Genet B Neuropsychiatr Genet 141B(8):935–938
Molero P, Ortuno F, Zalacain M, Patino-Garcia A (2007) Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 7(6):418–426
Schurhoff F, Szoke A, Chevalier F, Roy I, Meary A, Bellivier F, Giros B, Leboyer M (2007) Schizotypal dimensions: an intermediate phenotype associated with the COMT high activity allele. Am J Med Genet B Neuropsychiatr Genet 144B(1):64–68
Chen CY, Lu RB, Yeh YW, Shih MC, Huang SY (2011) Association study of catechol-O-methyltransferase gene polymorphisms with schizophrenia and psychopathological symptoms in Han Chinese. Genes Brain Behav 10(3):316–324
Li WJ, Kou CG, Yu Y, Sun S, Zhang X, Kosten TR, Zhang XY (2012) Association of catechol-O-methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population. Am J Med Genet B Neuropsychiatr Genet 159B(4):370–375
Wright GE, Niehaus DJ, van der Merwe L, Koen L, Korkie LJ, Kinnear CJ, Drogemoller BI, Warnich L (2012) Association of MB-COMT polymorphisms with schizophrenia-susceptibility and symptom severity in an African cohort. Prog Neuropsychopharmacol Biol Psychiatry 39(1):163–169
Schneider M, Van der Linden M, Glaser B, Rizzi E, Dahoun SP, Hinard C, Bartoloni L, Antonarakis SE, Debbane M, Eliez S (2012) Preliminary structure and predictive value of attenuated negative symptoms in 22q11.2 deletion syndrome. Psychiatry Res 196(2–3):277–284
Kang WS, Park JK, Park HJ, Kim SK, Cho AR, Lee SM, Kim JW, Song JY (2012) Association between catechol-O-methyltransferase Val158Met polymorphism and negative symptoms of schizophrenia in the Korean population. Psychiatry Res 198(2):338–339
Docherty AR, Sponheim SR (2008) Anhedonia as a phenotype for the Val158Met COMT polymorphism in relatives of patients with schizophrenia. J Abnorm Psychol 117(4):788–798
Tomppo L, Hennah W, Miettunen J, Jarvelin MR, Veijola J, Ripatti S, Lahermo P, Lichtermann D, Peltonen L, Ekelund J (2009) Association of variants in DISC1 with psychosis-related traits in a large population cohort. Arch Gen Psychiatry 66(2):134–141
Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, Rossi A, Pini S, Vita A, Cassano P, Stratta P, Severino G, Del Zompo M (2005) Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 52(2):83–89
Galderisi S, Maj M, Kirkpatrick B, Piccardi P, Mucci A, Invernizzi G, Rossi A, Pini S, Vita A, Cassano P, Stratta P, Severino G, Del Zompo M (2005) COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control study. Schizophr Res 73(1):27–30
Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Feiner D, Rotrosen J, Wolkin A (2000) Volumetric measure of the frontal and temporal lobe regions in schizophrenia: relationship to negative symptoms. Arch Gen Psychiatry 57(5):471–480
Wolkin A, Choi SJ, Szilagyi S, Sanfilipo M, Rotrosen JP, Lim KO (2003) Inferior frontal white matter anisotropy and negative symptoms of schizophrenia: a diffusion tensor imaging study. Am J Psychiatry 160(3):572–574
Szeszko PR, Robinson DG, Ashtari M, Vogel J, Betensky J, Sevy S, Ardekani BA, Lencz T, Malhotra AK, McCormack J, Miller R, Lim KO, Gunduz-Bruce H, Kane JM, Bilder RM (2008) Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 5:976–984
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Galderisi, S., Merlotti, E. & Mucci, A. Neurobiological background of negative symptoms. Eur Arch Psychiatry Clin Neurosci 265, 543–558 (2015). https://doi.org/10.1007/s00406-015-0590-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-015-0590-4